Lectins, E.g., Concanavalin, Hemagglutinin, Etc. Patents (Class 530/396)
-
Patent number: 6071885Abstract: This invention provides methods of inhibiting the export of a leaderless protein from a cell by contacting the cell with a cardiac glycoside or aglycone derivative. Leaderless proteins include FGF-1, FGF-2, IL-1.alpha., IL-1.beta. and factor XIIIa. These methods are useful in treatment of conditions, including tumors and diabetes.Type: GrantFiled: December 14, 1998Date of Patent: June 6, 2000Assignee: Scripps Research InstituteInventor: Robert Z. Florkiewicz
-
Patent number: 6054315Abstract: Methods for treating and modulating an inflammatory response using compositions containing a primarily monomeric or primarily dimeric form of galectin-1. The dimeric form stimulates apoptosis of activated neutrophils while the monomeric form inhibits apoptosis of activated neutrophils. Methods of screening for compounds which have galectin-1-like functions are also identified.Type: GrantFiled: September 5, 1997Date of Patent: April 25, 2000Assignee: The Board of Regents of the University of OklahomaInventors: Richard D. Cummings, Moon-Jae Cho
-
Patent number: 5981493Abstract: A method of treating an individual who is suffering from human immunodeficiency virus infection is disclosed. The method comprises administering to a human who is suffering from human immunodeficiency virus infection, an amount of ricin, abrin, modeccin, viscumin or volkensin effective to eliminate mononuclear phagocyte lineage cells.Type: GrantFiled: July 13, 1994Date of Patent: November 9, 1999Inventor: Robert P. LaGrone
-
Patent number: 5965712Abstract: CD23 is a low affinity receptor for IgE. The extracellular part of this molecule has been linked to a modified leucine zipper. This results in a trimeric configuration, since the stalk region of the CD23 molecule is itself a weak leucine zipper. This chimeric protein, designated LZ-CD23, interacts with IgE in a much stronger fashion than either simply the extracellular domain alone or the intact membrane CD23. This is the result of an increased avidity due to the stable trimeric configuration. The chimera has approximately at 10,000 fold increased ability to block IgE binding to mast cell/basophils, compared to native soluble CD23. At approximately equal concentrations to added IgE, 80% inhibition of IgE binding to Fc.di-elect cons.RI on mast cells was obtained. Thus, the LZ-CD23 chimera provides a new means for blocking and binding which provides benefits in the treatment of IgE-mediated asthma and allergic diseases.Type: GrantFiled: June 19, 1998Date of Patent: October 12, 1999Assignee: Virginia Commonwealth UniversityInventors: Daniel H. Conrad, Ann E. Kelly
-
Patent number: 5945514Abstract: The present invention relates to an antiviral raw material having mannose-binding type lectin bound, through a hydrophilic high-molecular chain, to a base material composed of a hydrophobic high-molecular chain. The raw material has excellent shape stability and at the same time has excellent antiviral activity so that it can be used in a wide range of fields.Type: GrantFiled: March 30, 1998Date of Patent: August 31, 1999Assignees: Mitsuru Akashi, Masanori BabaInventors: Mitsuru Akashi, Masanori Baba, Makoto Onishi
-
Patent number: 5929211Abstract: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.Type: GrantFiled: September 4, 1997Date of Patent: July 27, 1999Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Steven M. Chamow, Timothy P. Kogan
-
Patent number: 5929036Abstract: Fucosylated sialyated lactosaminoglycan structures that bind to GMP-140 have been discovered. The structure is created by expression of .alpha.(1,3) fucosyltransferases capable of modifying acceptors containing .alpha.(2,3) sialic acid-substituted lactosaminoglycans. Le.sup.x, Gal.beta.1,4(Fuc.alpha.1,3) GlcNAc.beta.1-R (where R is a protein or other carbohydrate structure), a common trisaccharide structure on myeloid cells but not on lymphocytes or erythroid cells, forms the core of this sialyated structure. The actual structure may be sialyl Le.sup.x, difucosyl sialyl Le.sup.x, a longer polyfucosylated polyactosaminoglycan, or a related variant. Several of these structures may bind to GMP-140 with various degrees of affinity. The carbohydrate structures, including sialyl Le.sup.x, difucosyl sialyl Le.sup.Type: GrantFiled: June 6, 1995Date of Patent: July 27, 1999Assignee: The Board of Regents of the University of OklahomaInventor: Rodger P. McEver
-
Patent number: 5895811Abstract: The invention relates to an artificial positive control reagents based on antibody conjugates that are used in immunochemical detection methods and to processes for the preparation of these reagents.Type: GrantFiled: June 5, 1995Date of Patent: April 20, 1999Assignee: Behring Diagnostics GmbHInventors: Stefan Brust, Heinz-Juergen Friesen, Guenther Nau, Hans-Erwin Pauly
-
Patent number: 5891855Abstract: This invention provides methods of inhibiting the export of a leaderless protein from a cell by contacting the cell with a cardiac glycoside or aglycone derivative. Leaderless proteins include FGF-1, FGF-2, IL,-1.alpha., IL-1.beta. and factor XIIIa. These methods are useful in treatment of conditions, including tumors and diabetes.Type: GrantFiled: February 12, 1996Date of Patent: April 6, 1999Assignee: The Scripps Research InstituteInventor: Robert Z. Florkiewicz
-
Patent number: 5889155Abstract: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue, allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.Type: GrantFiled: March 31, 1995Date of Patent: March 30, 1999Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Steven M. Chamow, Timothy P. Kogan
-
Patent number: 5880091Abstract: P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of ?.sup.3 H!glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells.Type: GrantFiled: June 7, 1995Date of Patent: March 9, 1999Assignee: The Board of Regents of the University of OklahomaInventors: Richard D. Cummings, Kevin L. Moore, Rodger P. McEver
-
Patent number: 5858368Abstract: A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a multivalent, preferably trivalent, influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant hemagglutinin antigens are full length, uncleaved (HAO), glycoproteins produced from baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions. The recombinant vaccine can be developed from primary sources of influenza, for example, nasal secretions from infected individuals, rather than from virus adapted to and cultured in chicken eggs. The process for cloning influenza hemagglutinin genes from influenza A and B viruses uses specially designed oligonucleotide probes and PCR. In the preferred embodiment, the cloned HA genes are then modified by deletion of the natural hydrophobic signal peptide sequences and replacing them with a new baculovirus signal peptide.Type: GrantFiled: May 30, 1995Date of Patent: January 12, 1999Assignee: Protein Sciences CorporationInventors: Gale E. Smith, Franklin Volvovitz, Bethanie E. Wilkinson, Andrei I. Voznesensky, Craig S. Hackett
-
Patent number: 5762939Abstract: A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a trivalent influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant hemagglutinin antigens are full length, uncleaved (HA0), glycoproteins produced from baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions. The process for cloning influenza hemagglutinin genes from influenza A and B viruses uses specially designed oligonucleotide probes and PCR. The cloned HA genes are then modified by deletion of the natural hydrophobic signal peptide sequences and replacing them with a new baculovirus signal peptide. A general approach for the efficient extraction and purification of recombinant HA protein produced in insect cells is also disclosed which can be adapted for the purification of rHA proteins from A sub-types and B type influenza viruses.Type: GrantFiled: September 13, 1993Date of Patent: June 9, 1998Assignee: MG-PMC, LLCInventors: Gale Eugene Smith, Franklin Volvovitz, Bethanie Eident Wilkinson, Craig Stanway Hackett
-
Patent number: 5760177Abstract: The invention provides a lipopolysaccharide (LPS) binding protein isolated from horseshoe crab. The LPS binding protein is isolated by (i) extracting the hemocyte membrane fraction of horseshoe crab with a polyethylene glycol ether type nonionic surface active agent in the presence of Ca ions, (ii) combining the extract with immobilized LPS under conditions that permit the LPS binding protein to bind the immobilized LPS to produce an LPS-LPS binding protein complex, and (iii) harvesting the LPS binding protein released from the complex in the presence of a chelating agent. The isolated LPS binding protein has a molecular weight of about 27,000 daltons as determined by SDS polyacrylamide gel electrophoresis and is operative to bind a lipopolysaccharide endotoxin. Accordingly, the isolated LPS binding protein can be used for detecting endotoxin and/or removing endotoxin from an injectable medicine.Type: GrantFiled: February 23, 1995Date of Patent: June 2, 1998Assignee: Seikagaku Kogyo Kabushiki KaishaInventors: Sadaaki Iwanaga, Shunichiro Kawabata, Tetsu Saito
-
Patent number: 5710257Abstract: Pharmaceutical compositions useful in the treatment of autoimmune conditions include as an active ingredient a soluble lectin having a molecular weight of about 14 kilodaltons or a fragment thereof. The lectin or fragment binds .beta.-galactoside-containing moieties independent of the presence or absence of Ca.sup.+2, stimulates hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays wherein the stimulation is inhibited by lactose or thiogalactoside, has an amino acid sequence containing at least one N-glycosylation site and is at least 90% homologous to the amino acid sequence shown in positions 2-135 of FIG. 1 or the relevant portions thereof. The composition is used for treatment of autoimmune conditions such as rheumatoid arthritis, myasthenia gravis, and multiple sclerosis, as well as modulating the immune response in an allergic reactions or to organ or tissue transplant rejection. The inventive composition can be combined with general immunosuppressants.Type: GrantFiled: September 25, 1996Date of Patent: January 20, 1998Inventors: Jeffrey J. Seilhamer, Glenn Nedwin, Tim Bringman, Pierre-Olivier Couraud
-
Patent number: 5693760Abstract: Pharmaceutical compositions useful in the treatment of autoimmune conditions include as an active ingredient a soluble lectin having a molecular weight of about 14 kilodaltons or a fragment thereof. The lectin or fragment binds .beta.-galactoside-containing moieties independent of the presence or absence of Ca.sup.+2, stimulates hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays wherein the stimulation is inhibited by lactose or thiogalactoside, has an amino acid sequence containing at least one N-glycosylation site and is at least 90% homologous to the amino acid sequence shown in positions 2-135 of FIG. 1 or the relevant portions thereof. The composition is used for treatment of autoimmune conditions such as rheumatoid arthritis, myasthenia gravis, and multiple sclerosis, as well as modulating the immune response in an allergic reactions or to organ or tissue transplant rejection. The inventive composition can be combined with general immunosuppressants.Type: GrantFiled: October 20, 1994Date of Patent: December 2, 1997Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jeffrey J. Seilhammer, Glenn Nedwin, Tim Bringman, Pierre-Olivier Couraud
-
Patent number: 5644035Abstract: A purified glycoprotein complex of over 1200 kD apparent native molecular weight having a sedimentation value of approximately 25S and having the ability to selectively bind human Mac-2 or interfere with PHA activation of lymphocytes, DNA sequences that encode the protein, and expression systems for expressing it, thus providing for medicaments that are useful for treating or diagnosing diseases, including cancer, infectious disease, and diseases of the immune system.Type: GrantFiled: June 7, 1995Date of Patent: July 1, 1997Assignee: Chiron CorporationInventors: Kirston E. Koths, Robert F. Halenbeck, Eric W. Taylor, Alice M. Wang, Clayton L. Casipit
-
Patent number: 5635384Abstract: The present invention is directed to a ribosome inactivating proteins. The proteins are characterized by being in a single chain proRIP inactive form that can be converted into an active form by cleavage with proteases.Type: GrantFiled: January 26, 1995Date of Patent: June 3, 1997Assignee: DowElancoInventors: Terence A. Walsh, Timothy D. Hey, Alice E. R. Morgan
-
Patent number: 5607920Abstract: The invention is directed to purified and isolated concanavalin A-binding proteins from chondrocytes that are not present in dedifferentiated cells from chondrocytes. The invention is also directed to a purified and isolated chondrocyte membrane protein, (CMP), which is a concanavalin A-binding protein, with a molecular weight of about 76 kD in SDS-PAGE. After treatment with endoglycosidase, CMP has an apparent molecular weight of about 67 kD. The N-terminal amino acid sequence and several internal amino acid sequences are given for CMP. These proteins can be used in assays, methods, or treatments involving differentiation of chondrocytes and the control of cartilaginous osteogenesis.Type: GrantFiled: July 21, 1994Date of Patent: March 4, 1997Assignee: Hoechst Japan LimitedInventors: Yukio Kato, Haiou Pan, Kazuyuki Doi
-
Patent number: 5587460Abstract: Human HL-60 lectin having an amino acid sequence different from other known animal lectins is disclosed. This is one member of a class of mammalian lectins extractable in lactose or detergent and specific for beta-D-galactosides (14-beta-gal lectin which contains at least one glycosylation site). Recombinant methods and materials for production of the mammalian 14-beta-gal lectins, especially HL-60 lectin, in a variety of hosts, and methods to utilize the resulting lectins are also described. Human HL-60 lectin is found in HL-60 cells and in placental tissue.Type: GrantFiled: August 5, 1994Date of Patent: December 24, 1996Assignee: Incyte Pharmaceutical CorporationInventors: Glenn E. Nedwin, Timothy S. Bringman, Pierre-Oliver Couraud
-
Patent number: 5585345Abstract: Extended forms of beta subunits of human glycoproteins wherein the amino acid sequence of a carboxy terminal peptide (CTP) representing positions from about 112-118 to 145 of the human CG-beta subunit or a variant form thereof is appended to the C-terminus are disclosed. Recombinant materials for the production of these extended human glycoprotein beta subunits and production of the modified hormones containing the extended beta subunits are also described. Pharmaceutical compositions containing the modified forms of these hormones are useful in pharmacological applications analogous to those of the unmodified forms.Type: GrantFiled: May 6, 1994Date of Patent: December 17, 1996Assignee: Washington UniversityInventor: Irving Boime
-
Patent number: 5559103Abstract: The present invention relates to bivalent sialyl Lewis X saccharide compounds that inhibit cellular binding to a selectin receptor. Pharmaceutical compositions containing a compound of Formula I, and processes for making and using the same are disclosed. A contemplated bivalent sialyl Lewis X saccharide compound has a structure that corresponds to Formula I, below, ##STR1## wherein R is a directly linked divalent monosaccharide unit; Y is selected from the group consisting of C(O), SO.sub.2, HNC(O), OC(O) and SC(O);R.sup.2 is selected from the group consisting of a C.sub.1 -C.sub.6 hydrocarbyl, an aryl, a substituted aryl and a phenyl C.sub.1 -C.sub.3 alkylene group, wherein an aryl group has one six-membered aromatic ring or two fused six-membered aromatic rings, which ring or rings are hydrocarbyl, monoazahydrocarbyl, or diazahydrocarbyl rings, and a substituted aryl group is a before-mentioned aryl group having a substituent selected from the group consisting of halo, trifluoromethyl, nitro, C.sub.1 -C.Type: GrantFiled: July 20, 1994Date of Patent: September 24, 1996Assignee: Cytel CorporationInventors: Federico C. A. Gaeta, Shawn A. DeFrees
-
Patent number: 5523395Abstract: Disclosed are two lectin species isolated from the hemolymph of Japanese horseshoe crabs and Southern horseshoe crabs which bind to N-acetylneuraminic acid and N-glycolylneuraminic acid, but not to N-acetylglucosamine, glucoronic acid, or N-acetylgalactosamine.Type: GrantFiled: July 20, 1994Date of Patent: June 4, 1996Assignee: Maruha CorporationInventors: Seiichi Ohkuma, Khomei Yanagi, Kuniharu Wada, Isami Tsuboi, Shoji Kimura, Masahito Matsukawa, Nobuyuki Sato
-
Patent number: 5508177Abstract: The present invention provides processes for isolating in substantially purified form water-soluble penicillin binding protein 2a of Staphylococcus aureus.Type: GrantFiled: May 14, 1993Date of Patent: April 16, 1996Assignee: Eli Lilly and CompanyInventors: Joe E. Dotzlaf, Sandhya K. Ghag, Wu-Kuang Yeh
-
Patent number: 5494800Abstract: A method of determining the presence and quantity of an analyte of interest in a particulate-containing sample is disclosed, as is a construct for use in the method. The method is particularly useful for determining an analyte in whole blood and in fermentation suspensions. The construct is comprised of a first moiety, which is a particulate-binding moiety and a second moiety, which binds the analyte of interest.Type: GrantFiled: April 29, 1994Date of Patent: February 27, 1996Assignee: CytoSignet, Inc.Inventor: Nathan L. Smith, III
-
Patent number: 5407454Abstract: Selected plant lectins have been found to be larvicidal against a number of common insect pests of agricultural crops. In a preferred embodiment, plant resistance to these insects is produced by inserting into the cells of a plant a gene whose expression causes production of one or more of these lectins in larvicidal amounts.Type: GrantFiled: September 20, 1991Date of Patent: April 18, 1995Assignee: Pioneer Hi-Bred International, Inc.Inventors: Anthony Cavalieri, Thomas Czapla, John Howard, Gururaj Rao
-
Patent number: 5405748Abstract: A simple immunoassay method is provided which distinguishes pathogenic from nonpathogenic forms Entamoeba histolytica in biological samples. This assay utilizes monoclonal antibody preparations which are specific for designated epitopes of the 170 kd subunit of the Gal/GalNAc lectin. When pathogenic forms, specifically, are to be detected, at least one antibody which is immunospecific for an epitope unique to the forms of the 170 kd lectin found in pathogenic strains is used in the assay. The invention further includes monoclonal antibodies which are immunospecific for epitopes 1-3 of the 170 kd subunit of the Gal/GalNAc lectin of either pathogenic or nonpathogenic forms and to monoclonal antibodies specifically immunoreactive with epitopes unique to nonpathogenic derived 170 kd subunit, as well as purified forms of the Gal/GalNAc lectin from both pathogenic and nonpathogenic forms.Type: GrantFiled: June 10, 1993Date of Patent: April 11, 1995Assignee: University of Virginia Patents FoundationInventors: William A. Petri, Jr., Jonathan I. Ravdin
-
Patent number: 5395924Abstract: An activated affinity ligand is described comprising: a ligand having (a) a region with affinity for binding sites of a lectin; and (b) a reactive group capable of covalently linking the ligand to the lectin to thereby block one or more of the binding sites of the lectin. A blocked lectin is described comprising one or more affinity ligands covalently linked by means of a reactive group present on each of the ligands to a lectin such that one or more binding sites of the lectin is blocked. A cell-binding agent-blocked lectin conjugate is described comprising the above-described blocked lectin and a cell-binding agent covalently linked to: (a) one of the covalently linked affinity ligands; or (b) the lectin. A method of preparing the cell-binding agent-blocked lectin conjugate is described. An affinity support capable of binding to a lectin to form a blocked lectin is described comprising an activated affinity ligand covalently linked to a solid support.Type: GrantFiled: February 19, 1993Date of Patent: March 7, 1995Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Walter A. Blattler, John M. Lambert, Victor S. Goldmacher, Ravi V. J. Chari, Charles F. Scott, Jr., Linda J. Kostuba, Simon E. Moroney, Albert R. Collison
-
Patent number: 5391715Abstract: A process is provided for the purification of pertussis toxin (PT) and/or filamentous hemagglutinin antigen (FHA) from a B. pertussis fermentation broth or cell free culture supernatant containing at least one antigen, which comprises contacting the fermenation broth or cell free culture supernatant with a hydroxyapatite adsorbent for a sufficient time to adsorb the antigen(s) at a pH which both PT and FHA are adsorbed and eluting a mixture containing the adsorbed antigen(s) from the adsorbent with eluant at a pH which both PT and FHA are eluted. The PT and FHA may be further purified by two sequential chromatographic columns, one of which involves apolar-ligand chromatography.Type: GrantFiled: March 24, 1992Date of Patent: February 21, 1995Assignee: SmithKline Beecham BiologicalsInventors: Carine Capiau, Pierre Desmons
-
Patent number: 5338835Abstract: The invention provides recombinant native and mutein forms of human reproductive hormones with characteristic glycosylation patterns which are influential in the metabolic activity of the protein. The invention also provides recombinant mutant forms of the human alpha subunit common to FSH, LH, CG, and TSH, to obtain hormones which also have unique glycosylation patterns. Also provided are recombinant materials to produce these subunits separately or together to obtain complete heterodimeric hormones of regulated glycosylation pattern and activity. Modified forms of LH and FSH beta subunits which enhance the rate of dimerization and secretion of the dimers or individual chains are also disclosed.Type: GrantFiled: September 24, 1992Date of Patent: August 16, 1994Assignee: Washington UniversityInventor: Irving Boime
-
Patent number: 5277892Abstract: Methods and reagents for the in vivo tagging of leukocytes, and in particular lymphocytes with a leukostimulatory agent and a linked medically useful metal ion, including a radioisotope, and subsequent detection of leukocyte or lymphocyte trafficking and sites of concentrated leukocytes or lympLICENSE RIGHTSThe U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of Small Business Innovative Research Grant No. 1 R43 AR41124 awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, Department of Health and Human Services.Type: GrantFiled: February 20, 1992Date of Patent: January 11, 1994Assignee: RhoMed IncorporatedInventor: Buck A. Rhodes
-
Patent number: 5276141Abstract: The invention proposes a process for purifying a highly glycosylated protein from a crude preparation which comprises the action (i) of adding to said preparation a divalent metal ion in a sufficient amount in order to form a mixture which precipitates and (ii) after precipitation, of harvesting said protein from the mixture supernatant.Type: GrantFiled: February 14, 1992Date of Patent: January 4, 1994Assignee: Transgene S.A.Inventor: Hanno Kolbe
-
Patent number: 5270200Abstract: Nucleic acid sequences encoding the Phaseolus vulgaris storage protein arcelin-1 are provided. These sequences are useful in providing transformed plant cells and plants which are insect-resistant.Type: GrantFiled: October 9, 1990Date of Patent: December 14, 1993Assignee: The Plant Cell Research InstituteInventors: Samuel S. M. Sun, Thomas C. Osborn
-
Patent number: 5250410Abstract: A method for the rapid identification and differentiation of HSV-1 and/or HSV-2 with fluorescein-conjugated Helix pomatia lectin. Clinical specimens are processed, with centrifugation, in pre-prepared shell vials of cell culture, with subsequent supplementation and 20 hour incubation (approximately) at 37.degree. C. Coverslips of the shell vials are then fixed, air dried, overlaid with fluorescein-conjugated Helix pomatia lectin, washed, dried, mounted and examined under a microscope equipped with an ultraviolet light source. The identification of fluorescence confirms herpes virus infection. Granular fluorescent patterns confirm presence of HSV-2 serotype and diffuse fluorescent patterns confirm presence of HSV-1 serotype.Type: GrantFiled: September 21, 1992Date of Patent: October 5, 1993Assignee: Allegheny-Singer Research InstituteInventor: Malcolm Slifkin
-
Patent number: 5239062Abstract: An activated affinity ligand is described comprising: a ligand having (a) a region with affinity for binding sites of a lectin; and (b) a reactive group capable of covalently linking the ligand to the lectin to thereby block one or more of the binding sites of the lectin. A blocked lectin is described comprising one or more affinity ligands covalently linked by means of a reactive group present on each of the ligands to a lectin such that one or more binding sites of the lectin is blocked. A cell-binding agent-blocked lectin conjugate is described comprising the above-described blocked lectin and a cell-binding agent covalently linked to: (a) one of the covalently linked affinity ligands; or (b) the lectin. A method of preparing a blocked lectin is described. A method of preparing the cell-binding agent-blocked lectin conjugate is described. An affinity support capable of binding to a lectin to form a blocked lectin is described comprising an activated affinity ligand covalently linked to a solid support.Type: GrantFiled: July 31, 1990Date of Patent: August 24, 1993Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Walter A. Blattler, John M. Lambert, Victor S. Goldmacher, Ravi V. J. Chari, Charles F. Scott, Jr., Linda J. Kostuba, Simon E. Moroney, Albert R. Collinson
-
Patent number: 5225542Abstract: Carbohydrate-binding proteins (lectins) of mammalian tumor cells and processes for their preparation. These lectins, the corresponding carbohydrates and the corresponding monoclonal antibodies are suitable for rapid, reliable and precise differential diagnosis of tumors and for the product of pharmaceutical compositions for the treatment of tumors.Type: GrantFiled: January 15, 1991Date of Patent: July 6, 1993Assignee: Max-Planck Gesellschaft zur Foerderung der Wissenschaften e.V.Inventors: Friedrich Cramer, Hans-Joachim Gabius
-
Patent number: 5185434Abstract: Prolonged-action immunotoxin consisting of a conjugate in which an antibody or antibody fragment is coupled, by means of a covalent structure containing a disulfide group or a thioether group, with a glycoprotein which inactivates ribosomes and has a prolonged action obtained by the oxidation of its saccharide units which periodate ions.Type: GrantFiled: March 2, 1989Date of Patent: February 9, 1993Assignee: SanofiInventors: Franz Jansen, Pierre Gros
-
Patent number: 5166320Abstract: A targetable gene delivery system is provided for introducing foreign genes into mammalian cells. The system employs a soluble targetable DNA complex and utilizes receptor-mediated endocytosis to endow cell specificity. The soluble DNA-carrying complex is formed by non-covalently binding a ligand conjugate with the foreign gene. The conjugate, in turn, is formed by bonding receptor-specific ligands such as asialoglycoproteins to polycations such as polylysine through covalent bonds such as disulfide bonds. The system exhibits a high degree of cell specificity and offers potential for the treatment of inherited genetic disorders.Type: GrantFiled: April 2, 1990Date of Patent: November 24, 1992Assignee: University of ConnecticutInventors: George Y. Wu, Catherine H. Wu
-
Patent number: 5162218Abstract: Polypeptide compositions are provided having a binding site specific for a particular target ligand and further having an active functionality proximate the binding site. The active functionality may be a reporter molecule, in which case the polypeptide compositions are useful in performing assays for the target ligand. Alternatively, the active functionality may be a chemotherapeutic agent, in which case the polypeptide compositions are useful for therapeutic treatment of various diseased states. A novel method for preparing such polypeptides having active functionalities proximate their binding site comprises combining the polypeptide specific for the target ligand with an affinity label including ligand having a reactive group attached thereto. The reactive group is then covalently attached to an amino acid side chain proximate the binding site and cleaved from the substrate. The substrate is eluted, leaving a moiety of the reactive group covalently attached to the polypeptide.Type: GrantFiled: June 10, 1991Date of Patent: November 10, 1992Assignee: The Regents of the University of CaliforniaInventor: Peter Schultz
-
Patent number: 5093475Abstract: Novel compounds and methods for the formation of disulfide linkages are presented. The novel compounds employed are substituted 2-iminothiolane hydrohalide linking agents of the following formula (I): ##STR1## wherein, X is halogen;R.sub.1 is COOR.sub.5 ; halogen; nitro; unsubstituted or halogenated C.sub.1-8 alkyl; unsubstituted or halogenated C.sub.1-8 alkoxy; unsubstituted or halogenated C.sub.2-8 alkenyl; unsubstituted or halogenated C.sub.2-8 alkynyl; unsubstituted C.sub.3-8 cycloalkyl; unsubstituted aryl; aryl substituted with 1 to 3 substituents selected from halogen, amino, unsubstituted or halogenated C.sub.1-8 alkyl, or unsubstituted or halogenated C.sub.1-8 alkoxy; unsubstituted heterocycle; or heterocycle substituted with 1 to 3 substituents selected from amino, halogen, unsubstituted or halogenated C.sub.1-8 alkyl, or unsubstituted or halogenated C.sub.1-8 alkoxy;each of R.sub.2, R.sub.3 and R.sub.4 is independently hydrogen or selected from the values of R.sub.1 ; orR.sub.1 and R.sub.Type: GrantFiled: December 21, 1989Date of Patent: March 3, 1992Assignee: Xoma CorporationInventors: Stephen F. Carroll, Dane A. Goff
-
Patent number: 5089604Abstract: A high molecular compound useful as a non-radioactive carrier, which comprises at least one unit of (1) an asialoglycoprotein acceptor-directing compound and at least one unit of (2) a chelate-forming compound chemically bonded thereto, and which may be labeled with a radioactive metallic element to give a radioactive metallic element-labeled product useful as a radioactive diagnostic or therapeutic agent for liver.Type: GrantFiled: October 18, 1989Date of Patent: February 18, 1992Assignee: Nihon Medi-Physics Co., Ltd.Inventors: Komei Washino, Miki Kurami, Nobuo Ueda
-
Patent number: 5079163Abstract: Ricin B muteins, ricin and ricin precursors having at least one amino acid of at least one galactoside binding site altered to decrease the binding of ricin B to galactosides are claimed. DNA sequences encoding the ricin B muteins, ricin and ricin precursor in which the B chain thereof is the ricin B mutein are claimed. Recombinant expression vectors effective in expressing the DNA sequences of the ricin B muteins, ricin and ricin precursors are claimed. Host cells transformed with the foregoing expression vectors are also claimed. Conjugates comprising binding moieties such as antibodies, hormones, and lymphokines bound to the ricin B mutein and ricin wherein the B chain thereof is the mutein is also claimed.Type: GrantFiled: March 12, 1987Date of Patent: January 7, 1992Assignee: Cetus CorporationInventors: Michael Piatak, Jr., L. L. Houston, Anne W. Emerick
-
Patent number: 5055455Abstract: A substantially pure capsular exopolysaccharide adhesin of coagulase-negative staphyhlococcal strains, and a general method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and monoclonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymeric medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by nosocomial coagulase-negative staphylococcal strains, in assays for the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.Type: GrantFiled: September 28, 1988Date of Patent: October 8, 1991Assignee: Brigham and Women's HospitalInventor: Gerald B. Pier
-
Patent number: 5053386Abstract: Compositions and methods of treatment comprising the lectins Abrin and Abrus agglutinin for the suppression of post-surgical malignant tumor metastasis are disclosed. Also disclosed is the administration of compositions and methods of treatment utilizing the above lectins in combination with either or both radiation treatment and/or chemotherapy.Type: GrantFiled: May 23, 1990Date of Patent: October 1, 1991Inventor: Ta C. Tung
-
Patent number: 5004608Abstract: Purified Gal/GalNAc adherence lectin of Entamoeba histolytica is used for development of a vaccine to prevent human amebiasis.Type: GrantFiled: December 29, 1989Date of Patent: April 2, 1991Assignee: The University of Virginia Alumni Patents FoundationInventors: Jonathan I. Ravdin, William A. Petri, Jr.
-
Patent number: 4997915Abstract: Lymphocytosis promoting factor (LPF) and filamentous hemaglutinin (FHA) are isolated from the growth medium of the Bordatella pertussis organism and purified by selecting adsorbing the LPF and FHA on a selective adsorbing medium, such as filter aids or gel filtration media, at low ionic strength and subsequently removing the adsorbed LPF and FHA at using an aqueous medium of high ionic strength, either simultaneously or sequentially. Prior to desorbtion of the LPF and FHA, the adsorbing medium may be contacted with an aqueous solution of a non-ionic detergent, which enables the LPF and FHA subsequently desorbed to be substantially free from contamination by lipopolysaccharides (LPS). The LPF and FHA may be further purified on hydroxyapatite. The LPF and FHA may be detoxified separately or together by contacting with a cross-linking agent, such as glutaraldehyde or formaldehyde, in the presence of an anti-aggregation agent.Type: GrantFiled: April 6, 1989Date of Patent: March 5, 1991Assignee: Connaught Laboratories LimitedInventors: Larry U. L. Tan, Dirk Alkema, Gail Jackson, Po S. Wah
-
Patent number: 4985543Abstract: Disclosed herein are lectins extracted form a plant of the class Dicotyledoneae and an antiretoviral drug comprising as an active ingredient an effective amount of the lectins.Type: GrantFiled: June 17, 1988Date of Patent: January 15, 1991Assignee: Kureha Kagaku Kogyo Kabushiki KaishaInventors: Norifumi Sugita, Koichi Niimura, Yoshiharu Oguchi, Kunitaka Hirose, Kenichi Matsunaga, Minoru Oohara, Shigeaki Muto, Junji Kakuchi, Takao Furusho, Chikao Yoshikumi, Masaaki Takahashi
-
Patent number: 4985541Abstract: Purified cytotoxic proteins for use within therapeutic compositions are disclosed. The proteins inhibit protein synthesis in vitro, exhibit abortifacient activity in mice, and contain proline residues with equivalent positions at residue 43 and residue 46 in ricin A-chain. A method for preparing such a cytotoxic protein from the tissue of Trichosanthes kirilowii is also disclosed. The proteins may also be used within a method for inhibiting protein synthesis in selected cells.Type: GrantFiled: April 10, 1987Date of Patent: January 15, 1991Assignee: ZymoGenetics, Inc.Inventors: John M. Maraganore, Wayne R. Kindsvogel
-
Patent number: 4962188Abstract: Conjugates comprising recombinant ricin toxin A chain and a binding moiety which may be an antigen binding portion selected from the group consisting of Fab, Fab' and F(ab').sub.2 fragments of monoclonal or polyclonal antibodies, hormones, lectins or other compounds that are recognized by cell receptors, are described and claimed.Type: GrantFiled: September 30, 1986Date of Patent: October 9, 1990Assignee: Cetus CorporationInventor: Arthur E. Frankel
-
Patent number: 4960756Abstract: A lectin like protein substance, method of obtaining same and a pharmaceutical agent containing the substance, as an effective ingredient. The substance is obtained through steps of cultivating a cell line stablished from Sarcophaga peregrina embryo to produce the substance in a culture medium, as product of the cell line, separating the refining the same. The substance shows an anti-tumor activity and thus is useful as an effective ingredient for medicines to cure cancers.Type: GrantFiled: August 28, 1987Date of Patent: October 2, 1990Assignee: Sanwa Kagaku Kenkyusho Co., Ltd.Inventor: Shunji Natori